1. Home
  2. SAVA vs CURR Comparison

SAVA vs CURR Comparison

Compare SAVA & CURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cassava Sciences Inc.

SAVA

Cassava Sciences Inc.

HOLD

Current Price

$2.03

Market Cap

96.1M

Sector

Health Care

ML Signal

HOLD

Logo Currenc Group Inc. Ordinary Shares

CURR

Currenc Group Inc. Ordinary Shares

HOLD

Current Price

$2.26

Market Cap

112.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAVA
CURR
Founded
1998
2013
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
96.1M
112.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SAVA
CURR
Price
$2.03
$2.26
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$5.00
$3.50
AVG Volume (30 Days)
620.4K
196.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$14.56
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.15
$0.33
52 Week High
$4.98
$4.68

Technical Indicators

Market Signals
Indicator
SAVA
CURR
Relative Strength Index (RSI) 43.01 63.49
Support Level $2.01 $2.12
Resistance Level $2.29 $2.34
Average True Range (ATR) 0.14 0.16
MACD -0.01 0.02
Stochastic Oscillator 13.21 84.91

Price Performance

Historical Comparison
SAVA
CURR

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

About CURR Currenc Group Inc. Ordinary Shares

Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.

Share on Social Networks: